from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2G0G6Sc
Saturday, January 26, 2019
Green Financial Advisor Makes the Case for a “Free Market” Carbon Tax
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2G0G6Sc
Memes In Winter
Another meme page. Continue reading →
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2UifJLi
California’s Wildfire History – in one map
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2FUeYoG
Climate Is a State of Mind
A recent survey by Yale and George Mason activists is another reminder that "climate change" is actually a branch of environmental psychology. Consider that "climate" is an human construct, defined as the pattern of weather we remember in our living space over seasons and years. And "climate change" is therefore an added belief that our expectations about future weather are uncertain and unreliable. And so, attitude surveys are a suitable way to explore an issue that is wholly a matter of public opinion, IOW a state of mind rather than a state of nature.
The survey is appropriately entitled: Climate Change in the American Mind. Title is link to the website for the 2018 edition, with earlier results back to 2008.
The resources there are informative, including articles expressing both satisfactions and disappointments with the levels of belief and concern expressed by survey participants. The compliant mass media cherry pick various findings, giving headlines like these.
"We've entered a new era" of climate concern, survey finds CBS
Americans Believe in Climate Change, But Not Climate Action NYmag
Yale Poll: Climate Change 'Personally Important' to Record Number of Americans EcoWatch
Most Americans Don't Know Vast Majority Of Scientists Agree On Climate Change CleanTechnica
Most Americans now worry about climate change—and want to fix it National Geographic
Poll Shows Most People Believe 'Global Warming is Happening' necn
Survey reveals 70% of Americans favour the environment over economic growth ClimateAction
What is the American Mindset according to the Survey?
So beyond details of particular responses, what can we learn from this series of polls about the American state of mind regarding global warming/climate change?
The specific questions and response patterns are at Appendix I: Data Tables & Sample Demographics
There are a lot of questions asked and answered, including exploring a complete range of feelings people have on the issue. I will summarize the central questions and the pattern of responses over the last decade.
Click on image to enlarge.
The core set of global warming beliefs are listed on the left. The marked lines show the % of responses each one achieved over the years. For example, over 50% agreed to four of them in 2018: GW is happening, GW is man made, Future generations will be greatly harmed and Most scientists agree. Other patterns are also of interest. Personal experience of GW effects is reported by almost 50%, while only 30% are very worried. Indeed, people are less concerned about harm to themselves or even the US, then they are fearful for Developing Countries (DCs) and for Future Generations.
Notice there is a general curve to most of the answer time series. Beliefs are only slightly higher in 2018 than they were in 2008. In general, the %s were flat or declining in this decade until starting to rise again around 2014. This points to the linkage between the opinions held by the public and the emphasis promoted in the mass media. Compare the curvature in the above graph with this chart of climate change coverage in leading US newpapers.
The chart and research and research come from International Collective on Environment, Culture & Politics, AKA ICECaP. Note the peaks in 2007-8 at the time of IPCC AR4 and Al Gore's Inconvenient Truth flick, and in 2009-10 around the time of the Copenhagen COP. The Climategate emails were also in the news in 2010, but for some reason newspapers were less interested in that aspect, the topic dropped in coverage.
The spike in 2013 coincides with Obama's SOTU speech featuring climate change as the "defining issue of our time." The rise in climate change coverage in recent years is a more complex matter.
Climate journalists (like most all journalists) have been obsessed with trashing Donald Trump, and climate change is mentioned often as a subset of Trump complaints. Consider this chart from Media Matters.
See that huge spike in the middle? That's from June 1, 2017, when President Donald Trump announced that he intended to pull the U.S. out of the Paris climate agreement. No other day in the last three years saw anywhere near that much coverage. When Trump stages an event related to climate change, the media snap to attention. The rest of the time it's like, "Climate what?"
That aligns with what Media Matters found when we looked at climate coverage on broadcast TV news programs in 2017: Trump dominated the news segments about climate change. Researchers at the University of Colorado Boulder, in the International Collective on Environment, Culture & Politics, reached a similar conclusion when they analyzed TV news coverage from November of this year: "In US television coverage of climate change or global warming in November 2018, 'Trump' was explicitly invoked over fourteen times more frequently than the words 'science' or 'scientists' together and nearly four times more frequently than the word 'climate' itself."
A research group at the University of Colorado-Boulder, the International Collective on Environment, Culture and Politics (ICE CaPs), produced the findings that illustrate how much climate coverage has been driven by President Donald Trump. It examined coverage last year in five major American newspapers: The Washington Post, The Wall Street Journal, The New York Times, USA Today, and the Los Angeles Times. In the 4,117 stories in those papers that mentioned "climate change" or "global warming," the word "Trump" appeared 19,184 times — an average of nearly 4.7 times per article.
Summary
There is not much upward movement in public belief in global warming/climate change. There is increased attention from the left-leaning media as part of their general dislike of the Trump administration. One more time, who made global warming into a political rather than a scientific issue?
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2UjJN9g
Oh NO, It’s BONO!
By Paul Homewood
h/t Patsy Lacey
Shouldn't silly little girls like this be at school?
A teenage activist has told the global elite at the World Economic Forum (WEF) in Davos that they are to blame for the climate crisis and that the "house is on fire".
The Swiss summit is characterised as a discussion of momentous issues like Brexit, world trade and global warming.
Environmentalists have been complaining of alleged hypocrisy after reports that a record number of flights by carbon-spewing private jets would ferry rich corporate bigwigs to talk at the event this year.
Greta Thunberg, a Swedish 16-year-old, whose speech to a climate conference in December went viral, was speaking on a panel with musicians Bono and Will.I.Am when she brought up the issue.
"Some people say that the climate crisis is something that we will have created, but that is not true, because if everyone is guilty then no one is to blame. And someone is to blame," Greta said.
"Some people, some companies, some decision-makers in particular, have known exactly what priceless values they have been sacrificing to continue making unimaginable amounts of money. And I think many of you here today belong to that group of people."
Greta, who got a waiver from school to travel 32 hours from her home in Sweden – by train, to keep her carbon footprint down, said she wanted those in the audience to "panic".
"I want you to feel the fear I feel every day. We owe it to the young people, to give them hope. I want you to act … as if the house was on fire. Because it is," she added.
There was apparently a short pause in the room before U2 front man Bono started clapping, according to CNN.
The conference centre in the ski resort of Davos is bustled with business executives, presidents and prime ministers, heads of non-governmental organisations, scientists, and artists.
Several hundred environmentalists and political activists have bene protesting and waving green and red flags to demonstrate their opposition to the WEF and capitalism.
Greta too is a keen activist and has been staging weekly sit-ins outside the Swedish parliament. She says she will not stop until her country is in line with the Paris Agreement.
https://uk.news.yahoo.com/davos-2019-swedish-teenage-activist-201828107.html
But the biggest joke is that tax dodger Bono even dared to be there, never mind clap.
Could this be the same Bono who narrowly escaped death after his private jet door fell off in 2014?
Or the same Bono who flew into Sydney on a private jet, during his 2010 tour?
http://www.zimbio.com/pictures/YsPBx62sO-9/Bono+Boards+a+Private+Jet/6bygDqA17_r/Bono
Or the same Bono who loves to flaunt his luxury private yacht?
http://www.celebsonyachts.com/inside-look-bonos-secret-yacht-is-called-kingdom-come/
Perhaps little Greta should be more careful who she shares panels with in future.
But I wonder who paid her fare?
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2Uia0oX
Al Gore, UN Officials Team Up To Push A ‘New Deal For Nature’
http://bit.ly/2Wlgll7 The United Nations has joined forces with former Vice President Al Gore to promote a sweeping environmental agenda that seems all too familiar: a "New Deal For Nature." The U.N. is calling for a "New Deal For Nature" ahead of a biodiversity summit in 2020 where some sort of global compact is expected to [...]
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2RPrXhM
Long-term spatiotemporal variations of atmospheric sulfur, nitrogen and particle pollutants in Chongqing, southwest China: implication of industrial transfer
Abstract
Industrial transfer has swept through in China. However, there is still a knowledge gap about its environmental effects. In this study, industrial transfer status was assessed and evaluated by industrial ratios (%; the gross product contributions of the secondary industry to the whole industry) and the impact of such transfer on atmospheric environment (SO2, NO2, PM10 (particles with aerodynamic diameter less than 10 μm), precipitations of SO42−, NO3−, and NH4+) in the 38 districts and counties in Chongqing was analyzed and discussed for the period of 2006–2015. Results showed that industries were transferred obviously from the main urban region (MUR) into the 1-h economic region (OHER). Atmospheric sulfur and PM10 were efficiently put in control, but atmospheric nitrogen (NO2; precipitations of NO3− and NH4+) was increasing and posted a potential threat to air quality especially during 2011–2015. Correlations showed that industrial ratios had significantly positive relationships with concentrations of ambient SO2 and PM10 in the MUR and ambient NO2 in the OHER (p < 0.05) while a remarkably negative one with concentrations of ambient SO2 in the OHER (p < 0.05) during 2006–2015, implying that industrial transfer could be effective in transferring sulfur pollution but not as efficient in transferring atmospheric nitrogen and PM10 pollutions as SO2 between in the MUR and OHER. More measures should be taken to reduce nitrogen and PM10 emission and a regional monitoring network of ambient NH3 is in urgent need.
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2G2LR1z
Are Studies of High Penetrations of Wind Power Valid?
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2UjNf3T
Claim: compressed air in underground rocks could be the next batteries
Scottish offshore wind project [image credit : urbanrealm.com]
The very fact that these kinds of idea are being put forward is another admission that renewables are chronically intermittent and unreliable as electricity generators. We're told 'considerable investment' would be needed but ignore the fact that, for less cost and complexity, some reliable new gas power stations would be a far more practical plan.
By pumping compressed air into porous rocks deep under the sea floor, scientists think we could effectively store energy for months at a time, says Discover magazine.
With reports about climate change becoming increasingly dire, it's increasingly important to find an eco-friendly way to not only generate energy, but also store it.
After all, wind turbines and solar power and the like don't run steadily. So we can't just stick that extra energy in a bottle to use when the wind dies down and the sun sets.
Only no, that's almost exactly what a group of Scottish scientists is proposing. Except, in this case, the bottle is a layer of porous rocks deep within the sea bed, and the energy comes from compressed air.
You simply [sic] use your renewable energy source to compress and store the air, and then when you need the energy again you pop the cork, so to speak, and let the escaping air drive a turbine that re-generates the electricity. (Thanks to the extreme pressures down there, the air would stay in place, and not escape on its own.)
The researchers unveiled the details behind the plan, dubbed porous media compressed air energy storage (PM-CAES), in a Nature Energy paper this week. It's a simple-sounding mix of technologies that could seriously make a dent in a country's energy production — and mitigate the trends that are pushing the global climate to extremes.
Compressed Air of Superiority
Currently this plan is all theoretical — the paper just runs the numbers on the idea to see if it's at all practical. But boy, does it seem to be.
The authors specifically looked at how a PM-CAES system could work for the United Kingdom, using the sandstone deep below the waters of the North Sea. They looked at existing geological records to model the terrain, and assumed the air "wells" would be physically near to the energy sources they'd be storing — offshore wind turbines, for example.
According to the researchers, it could really work.
Continued here.
– – –
Nature Energy article: Inter-seasonal compressed-air energy storage using saline aquifers
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2HvDNZL
Spot The Volcano, 1815 Edition
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2UirRw4
Week in review – science edition
by Judith Curry
A few things that caught my eye this past week.
Important new paper analyzing troposphere/stratosphere measurements and implications for understanding climate change [link]
Atmospheric circulation as a source of uncertainty in climate change projections [link]
Heinrich events show two-stage climate response in transient glacial simulations [link]
Diagnosing the impacts of Northern Hemisphere surface albedo biases on simulated climate [link]
Towards operational prediction of near-term climate [link]
Rapidly receding Arctic Canada glaciers revealing landscapes continuously ice-covered for more than 40,000 years [link]
Implications for Lindzen's iris hypothesis: Self-aggregation of deep convection and its implication for climate [link]
Any influence of the 11-year solar cycle in the winter North Atlantic Oscillation is not significant. [link]
Ocean mesoscale mixing linked to climate variability [link]
What Thwaites glacier can tell us about the future of West Antarctica [link]
Four decades of Antarctic Ice Sheet mass balance from 1979-2017 [link]
Massive controversy, including attacks on dissenting scientists: How much can forests fight climate change? [link]
"We conclude that the QBO can potentially provide another source of skill for Northern Hemisphere winter prediction" [link] …
Aerosol-driven droplet concentrations dominate coverage and water content for oceanic low level clouds – key cloud feedback [link]
Modeling the recent changes in the Arctic Ocean CO2 sink (2006–2013) [link]
Snow cover trends in Finland over 1961‐2014 based on gridded snow depth observations [link]
Timescale for detecting the climate response to st ratospheric aerosol geoengineering [link]
(Re)presenting urban heat islands in Australian cities: A study of media reporting and implications for urban heat and climate change debates [link]
Are the near-Antarctic easterly winds weakening in response to enhancement of the Southern Annular Mode? [link]
The solar cycle's potential impact on weather and climate [link]
Exploring uncertainty in streamflow estimates [link]
The effect of Arctic sea‐ice loss on the Hadley circulation [link]
Why Antarctica's sea ice cover is so low (and no, it's not just about climate change) [link]
Coupled ocean-atmosphere interactions that lead to the extreme 2017 Coast El Niño event [link]
A reconciled estimate of the influence of Arctic sea-ice loss on recent Eurasian cooling [link]
20th century redistribution in the drivers of global tree growth [link]
Global atmospheric CO2 inverse models converging on neutral tropical land exchange, but disagreeing on fossil fuel and atmospheric growth rate [link]
Permafrost is warming at a global scale [link]
Ocean Circulation Signatures of North Pacific Decadal Variability [link]
"Although the amount of water contained in the snowpack has declined over the past century, it has been surprisingly stable since the 1980s, despite 1 °C of warming over the same period. " [link]
1D scaling analysis of the ice dynamics suggests that the currently destabilized glaciers are the fastest of all possible MIS-instabilities in #Antarctica. [link]
New insight from CryoSat-2 sea ice thickness for sea ice modelling [link]
Clarifying the relative role of forcing uncertainties and initial‐condition unknowns in spreading the climate response to volcanic eruptions [link]
How Ningaloo Nino supercharges El Nino [link]
A decadal dataset of global atmospheric dust retrieved from IASI satellite measurements [link]
Greenland Near-Surface Land Air Temperature Data from Berkeley Earth Present Some Surprises [link]
Heterogeneous changes in western North American #glaciers linked to decadal variability in zonal wind strength. [link]
Uncertainty representations of sea level rise: a telephone game? [link]
Arctic sea ice (Barents-Kara Sea) anomalies can modulate vertical wave propagation and stratosphere-troposphere coupling in weak polar vortex events [link]
Millennial‐scale Vulnerability of the Antarctic Ice Sheet to Regional Ice Shelf Collapse [link]
Significant Biologically‐mediated CO2 Uptake in the Pacific Arctic During the Late Open Water Season [link]
Irrigation in the Indian subcontinent strongly modulates water budget and land surface temperature [link]
Adapting attribution science to the climate extremes of tomorrow [link]
Social science, technology & policy
Article says high-pressure air in deep saline aquifers could store immense amounts of energy, sufficient to keep the lights on in Britain for a couple of months. [link]
Some of the best environmental #peacebuilding work in the world is currently taking place in Wadi El Ku, Sudan. A @UNEnvironment project has helped triple crop yield, increase farmers' income, and improve community-based natural resources management [link]
Incorporation of inland flooding into hurricane evacuation decision support modeling [link]
for Minnesota, it is cheaper to overbuild (and curtail) renewable energy than it is to build long-term storage. [link]
Warming trends in summer heatwaves [link]
German wine makers see boon in climate change [link]
EC Report: Climate Change Adaptation: research, science and innovation [link]
Second largest earthquake in South Korean history tied to geothermal plant [link]
Reshaping Africa's rural food systems and cutting food losses [link]
Factors influencing the adaptation of farmers in response to climate change: a review [link]
US Oil Boom Is Headed Into Uncharted Territory — 12 Million Barrels Per Day [link] …
Groundwater monitoring reports at #coalash sites are starting to show widespread contamination from health-harming heavy metals like arsenic. [link]
.
About science & scientists
This is not reality: excellent analysis of uncertainty and validation in modeling [link]
Feeling Exhausted. That's how many #womeninscience feel having to fight the constant battles, big and small. [link]
Long but fascinating read: Is ancient DNA research revealing new truths, or falling into old traps? [link]
Finally, a good paper on 'motivated reasoning'. [link]
"Our habit of dismissing the doomsday messages broadcast by right-wing media has prevented those of us on the left from getting an accurate read on the state of campus free expression." [link]…
"The National Science Foundation and philosophy of science's withdrawal from social concerns." [link]
New Institute for Integrity in Science [link]
Listening to people who think we are wrong [link]
Scientific progress is build on failure [link]
Problems with second-order logic: Metalogic and the overgeneration argument [link]
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2B5nXiC
Weekend Unthreaded
…
Rating: 0.0/10 (0 votes cast)
Rating: 0.0/10 (0 votes cast)
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2CLG90U
The Green Energies Of Instability…Swiss Power Grid Requires 200 Fold More Intervention Than 8 Years Ago!
Switzerland's power grid operator, Swissgrid, seems to have its hands full nowadays.
Just less than 10 years ago, Switzerland's power grid was among the most stable worldwide, operating with the same efficiency as its famous Swiss-made watches.
Today however, thanks to green energies like wind and sun, this is no longer the case, so reports the country's Baseler Allgemeine Zeitung (BAZ).
According to the BAZ, "In 2011 Swissgrid, the operator of the Swiss electricity grid, only intervened twice in the electricity grid to prevent major problems."
But last year, in order to keep the power supply stable, "these interventions reached a new record number with 382 interventions."
In other words, on average more than once a day. Hence the article by the BAZ is titled: "The power grid is fluctuating like never before."
The number of interventions needed to keep the Swiss power grid stable jumped from just 2 in 2011 to 382 last year, a new record. Chart source: Swissgrid, via BAZ.
Stabilizing the Swiss grid can mean throttling one or more of its dozen power plants, says the BAZ. Power fluctuations in the grid not only heighten the risk of overload and blackouts, but also threaten sensitive production equipment which rely on a steady supply of power for critical process control.
The BAZ adds that the problem is not only getting worse in Switzerland, but also in all the grids in neighboring countries, such Germany, France, Austria and Italy.
What's the reason for all the instability? The BAZ reports:
With more and more electricity from the sun and wind, whose production depends on the weather changing at short notice, it is becoming increasingly difficult to ensure an even supply. The production of these renewable electricity producers is much higher than consumption in wind and sunshine, but too low at night and when there is no wind."
The BAZ also notes that Switzerland is sorely lacking in energy storage systems to balance out the peaks that are seen in sun and wind power production.
"Customers bearing the costs"
The Swiss daily also writes that the country's power grid at times is so unstable that on July 2 (2018) alone, Swissgrid "had to throttle power plants eight times or have them started up so that grid operation was not endangered."
In Switzerland, whenever a power plant is asked to throttle its power production in order to keep the green-energy-flooded grid stable, it is entitled to financial compensation. No problem here: The power consumers pick up the tab, reports the BAZ.
When asked why the grid has become increasingly unstable with each passing year, Swissgrid replied that it was "due to sun and wind energy", the BAZ reports.
Europe dodged a bullet two weeks ago
Not only the Swiss power grid has been rickety and unstable, but so has the entire European grid, writes the BAZ. An example of this occurred recently, Swissgrid here reported in a press release:
A drop in frequency on the synchronously interconnected Continental Europe system was registered on 10 January 2019 at around 21.00.
The causes of this drop are still under investigation by the transmission system operators (TSOs) of ENTSO-E Regional Group Continental Europe.
A mismeasurement on lines between Germany and Austria was identified and corrected by TenneT Germany. However, this mismeasurement cannot explain the entire frequency drop on 10 January. The investigation, which is still on-going, is reviewing the significant variation in European production around 21.00 which coincided with changes in trade between different countries.
The frequency drop was sufficient to alert the TSOs but did not at any moment endanger security of supply.
TSOs of ENTSO-E Continental Europe Regional Group are taking collective actions to restore frequency as foreseen in such cases and continue their technical analysis of the incident."
Next time Europeans may not be so lucky.
Unfortunately it may just take a widespread blackout to get European leaders back to their senses. But even then, don't count on it. Some policymakers are in fact insisting that the grid instability problems can be solved by "adding more wind and solar power."
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2RSUrr4
Harrabin Peddles Latest Arctic Nonsense
By Paul Homewood
More nonsense from Roger Harrabin:
A rapid climate shift under way in the Barents Sea could spread to other Arctic regions, scientists warn.
The Barents Sea is said to be at a tipping point, changing from an Arctic climate to an Atlantic climate as the water gets warmer.
A conference in Norway heard that the Kara Sea and the Laptev Sea – both further to the east – are likely to become the new Arctic frontier.
The scientists warn that it will affect ecosystems.
It may also impact on global weather patterns, although there's no agreement on that.
They're concerned because the north Barents Sea has been governed by an Arctic climate since the end of the last Ice Age, 12,000 years ago.
The Arctic Ocean has a cold, fresh surface layer which acts as a cap on a layer of warm, saltier Atlantic water beneath.
But now in the Barents Sea there's not enough freshwater-rich sea-ice flowing from the high Arctic to maintain the freshwater cap.
And that's allowing warm, salty Atlantic water to rise to the surface.
In what's known as a feedback loop – the more the layers mix, the warmer the surface gets. And the warmer the surface gets, the more the waters mix.
So it's now only a matter of time, the researchers say, before this section of the Arctic effectively becomes part of the Atlantic. It could happen in as little as a decade, they warn….
And in another puzzle, freshwater in the western Arctic seems to be increasing as it diminishes in the eastern Arctic. Scientists are still struggling to fathom the complexities of human impact on the planet.
https://www.bbc.co.uk/news/science-environment-46976040
Why on earth should any of this have to do anything to do with "human impact on the planet"?
You only have to go back to the 1920s to see exactly the same climatic changes in that part of the Arctic.
https://journals.ametsoc.org/doi/abs/10.1175/1520-0493%281922%2950%3C589a%3ATCA%3E2.0.CO%3B2
This period, called the Warming in the North, is well known to scientists, and lasted from around 1920 to 1960.
Bob Dickson and Svein Osterhus wrote extensively about it in their seminal paper, "One hundred years in the Norwegian Sea":
As our hydrographic time series is lengthened into the middle decades of the 20th century, it begins to capture evidence of one of the largest and most widespread regime shifts to affect our waters within the modern instrumental record. These were the decades of 'the Warming in the North', when the salinity of North Atlantic water passing through the Faroe-Shetland Channel into the Norwegian Sea reached a century-long high (Dooley et al. 1984), when salinities were so high off Cape Farewell that they were rejected as erroneous (Harvey 1962) and when a precipitous warming by more than 2°C in the 5-year mean pervaded the West Greenland banks (Fig. 6), and also when the northward dislocations of biogeographical boundaries for a wide range of species, from plankton to commercially important fish, terrestrial mammals, and birds, were at their most extreme in the 20th century. The astonishing nature of these radical events is vivid in the contemporary scientific literature, most notably in the classic accounts by Knipowitsch (1931), Sæmundsson (1934), Hansen et al. (1949), Stephen (1938), Jensen (1939), Tåning (1943), Tåning (1949), Fridriksson (1949), and many others summarized in a comprehensive bibliography by Arthur Lee (1949) and reviewed in an ICES special scientific meeting on 'Climatic Changes in the Arctic in Relation to Plants and Animals' in Copenhagen in 1948.
https://www.tandfonline.com/doi/full/10.1080/00291950701409256
The Warming in the North ended abruptly in the 1960s, when Arctic currents took over again, and brought the sea ice back.
Go back a bit further, and we can see how sea ice around the Barents Sea fluctuated backwards and forwards:
And go back 3000 years, and we can see that current sea ice extent to the north of Iceland is near historical highs.
It should not take Harrabin more than a few minutes to check this out for himself. So why does he continue to peddle every bit of junk science he is fed?
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2MAPRaX
Growth of legal pot farms drives smog worries
From Science Mag Leaf enclosure measurements for determining volatile organic compound emission capacity from Cannabis spp. Summary Air pollution researchers are going to pot. The expansion of legal pot farms in the 10 U.S. states and Washington, D.C., that have legalized recreational marijuana has researchers and regulators concerned about their impacts on air quality and…
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2Wl5APX
This Week In Doom — Celebrity Meat Edition
Item Abortion until birth in New York State.
In a democracy, what is voted yes on becomes both true and moral. Maranatha.
Item Everyone Stop Everything. What Is This?
A lot of weird stuff shows up on the Internet, but Bite Labs is really, really weird. The site claims to be collecting tissue samples from celebrities, isolating the muscle stem cells, growing celebrity meat in "proprietary bioreactors," and then turning it into artisanal salami. Wut?
From the BiteLabs' website:
"We mix celebrity and animal meats, grown in house through a proprietary culturing process, into curated salami blends. Our process yields high-quality, luxury protein, in a sustainable manner that eliminates the environmental and ethical concerns associated with traditional livestock production."
Yup. No obvious ethical concerns here. Nothin' to see. This must be a hoax, right? Or a marketing campaign that wants to go viral (in which case we're helping). So far the BiteLabs Tumblr isn't revealing much. Neither is #EatCelebrityMeat.
Gives new meaning to the terms beefcake and (forgive me) piece of ass.
Besides the opportunities for hilarity and our culture's obsession with entertainers, there is a deeper trend here. We have seen in other places attempts to make meat from bugs in a large-scale manner, and also "meat" from petri dishes. We are losing the ability to tell man from animal, a difficult even pagans did not face. Yet we do. If animals are people, too, then of course they must have "rights" and cannot be eaten. That they eat each other is brushed aside.
What about plants? Surely they don't have "rights"?
Item Another Push for Plant "Rights"
Rejecting human exceptionalism leads from one bizarre concept to the next, including the ridiculous anthropomorphized idea that plants are persons too.
The New York Times published a professor (of course!) claiming that peas are "not only a what, but a who." The paper's science writer Natalie Angier even wrote that plants are "ethical autotrophs."
Trees as "Beings"
And now an Australian scientist has written a book claiming trees and other plants should be considered "beings" instead of "objects." From the Sydney Morning Herald story:
"It's OK to cut down a tree, or poison a weed, because plants don't feel pain when we chop them down, right? They don't have brains. Everyone knows that.
But plants make sounds — little underground clicks that microbes and insects might be able to hear. They communicate with each other, and other species, using chemicals…
'We have studied plants for a long time, but we only understand them as objects — not as beings,' says Associate Professor Monica Gagliano, a plant biologist at the University of Western Australia who conducted those studies. 'And if they are beings, then maybe they have rights? Definitely the right to be treated with respect and care — which we don't always do well.'"
Scoff as you like. But SJWs go from success to success. Every idiotic and foolish idea they have has the habit of becoming ensconced in law. They rely on people laughing at them but doing nothing. They know that most people will cower under their glare, once it's turned on them.
Right now, though, the SJWs have to battle Big Ag. It's one thing to claim corn cries, but it's another to muscle Monsanto into forgoing farming.
That means we'll likely see "studies" and "research" with "proves" that the least profitable plants are those that truly have feelings, while GMO cash crops, like corn, soy, and wheat, have had all feelings genetically modified out of them.
Write this one down, folks. You'll remember it in a year or two.
The Coriolis reception brings together lesbian-gay-bisexual-transgender-queer (LGBTQ) friends and allies to mentor, network, and connect with individuals who share common professional and personal interests. The 10th year Coriolis reception …
Question: What does interest or participation in non-procreative sexual simulation have to do with fluid flow on a rotating sphere? Answer: Not one damn thing.
Science is becoming increasingly woke.
Item Lesbian Couple Identifying As Straight Couple Prepares To Transition 5-Yr-Old Son Into A Daughter
The headline is enough. We can only imagine the alleged parents of this poor child to say someday, "Who knew I'd wind up in Hell?"
Many people find math frustrating.
But for some, it can actually turn into 'statistics anxiety,' a fear of doing math or statistics problems that can be debilitating or even stand in the way of graduation.
A new study from the University of Kansas discovered which factors can contribute to statistics anxiety and how it can be dealt with.
Previous studies have shown that some 80 percent of college students suffer from statistics anxiety, the University of Kansas explained.
'We teach a statistics class in the psychology department and see many students put it off until senior year because they're scared of this class,' Michael Vitevitch, professor and chair of psychology at the University of Kansas, said in a statement.
I used to have this power — to inflict statistics anxiety. But I am no longer a danger to the kiddies.
Item Why aren't doctors speaking of reality against tranny madness?
If you wonder why physicians aren't speaking up, I know of one just now who was mocked, threatened, and doxxed. All because he dare question, the paradigm of blocking normal puberty and wrecking child/adolescent bodies with high dose wrong sex hormones. /1
— Michael K. Laidlaw, MD (@MLaidlawMD) January 25, 2019
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2DAgH05
The UN’s Global Green Law is going nowhere for now
It may have taken a knock, but it's by no means the last we'll hear of it, as CFACT explains.
The first major meeting of the UN's (take a breath) "Ad hoc Open-ended Working Group towards a Global Pact for the Environment" or simply OEWG, convened on Monday, 14 January 2019 at the United Nations Environment Program offices in Nairobi, Kenya.
During the week-long session, delegates considered the report of the United Nations Secretary-General (UNSG), titled "Gaps in international environmental law and environment-related instruments: towards a global pact for the environment."
This is the newly hatched grand green dream, for a binding set of new global laws that both encompasses and surpasses all of the existing multinational environmental treaties and agreements (MEAs). I am not making this up.
Not surprisingly this wackiness originated in France, where President Macron wants to be the green king of the world.
Introduced at the 72nd session of the UN General Assembly in 2017 by Macron, the pact began its voyage through the UN system, and UN General Assembly resolution 72/277 subsequently established the OEWG with a mandate to submit its recommendations in the first half of 2019.
About 300 participants attended the meeting, especially government delegates from many countries, including the U.S., plus representatives of various international and UN organizations.
The good news is that the meeting turned into something of a fiasco. It turns out that the countries are not excited about surrendering their treaties and agreements.
The issue is so-called "gaps" in the existing legal system, at least according to the Secretary-General's contentious report. Many delegates, including America's, said they were biased wishes, not gaps. In fact they were seen by many countries as attacks on existing laws and agreements.
The Trump team was quite aggressive, but so were many others.
Continued here.
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2WmCEXD
Sonophotocatalytic treatment of rhodamine B using visible-light-driven CeO 2 /Ag 2 CrO 4 composite in a batch mode based on ribbon-like CeO 2 nanofibers via electrospinning
Abstract
CeO2/Ag2CrO4 composite photocatalyst was successfully fabricated using electrospinning and calcination and chemical precipitation method based on CeO2 ribbon-like fibers and characterized by field-emission scanning electron microscopy (FESEM), energy dispersive X-ray (EDX), X-ray diffraction (XRD), UV–Vis diffuse reflectance spectroscopy (DRS) and Fourier-transform infrared spectroscopy (FT-IR). The as-obtained CeO2/Ag2CrO4 composite used photocatalytic performance in the sonophotodegradation of rhodamine B in aqueous solution under visible-light (LED) irradiation. DRS analysis illustrates that CeO2/Ag2CrO4 composite exhibited enhanced absorption in the visible region-attributed CeO2 nanofibers. The effect of four effective parameters including initial concentration of rhodamine B (RhB), photocatalyst dosage, pH, and irradiation time was studied and optimized using central composite design. The kinetic studies confirmed ability of pseudo first-order reaction based on the Langmuir–Hinshelwood model for fitting empirical data, while its rate constant (kobs), L–H rate constants (kr), and L–H adsorption constants (KA) were 0.0449 min−1, 11.66 mg L−1 min−1 and 1.09E−3 mg L−1, respectively. The enhanced photocatalytic activity could be ascribed to the ultrasound field and formation of a heterojunction system among CeO2 and Ag2CrO4, which lead to a better mass transfer and higher efficiency of charge electron–hole separation, respectively.
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2B5hBA5
Chironomid genera distribution related to environmental characteristics of a highly impacted basin (Argentina, South America)
Abstract
The objective of the present study was to investigate the responses of the chironomid communities (Diptera: Chironomidae) to environmental variables in four moderately and highly disturbed rivers located in one of the most degraded watersheds in South America. Sampling campaigns were carried out during 2014–2016 in four sites of the Matanza-Riachuelo basin. The physical-chemical and hydrological variables were measured and, the ecological indices were calculated and evaluated by ANOVA. The responses of Chironomidae to the environmental variables were evaluated by redundancy analysis (RDA), and the sampling sites were grouped according to the populations of chironomids and the main environmental variables. Finally, the Spearman correlation was made to determine which of these variables were significant. In total, 13 chironomid taxa were found in 36 samples during the study period. The greatest density registered belongs to Rheotanytarsus and Cricotopus. The ANOVA detected the greatest Chironomidae density and taxonomic richness in the sites with agricultural-urban impact. The changes in the distribution of Rheotanytarsus, Thienemanniella, and Polypedilum were mainly explained by the increase in current velocity, organic matter, and hardness, and the decrease of NH3 and BOD. On the other hand, Goeldichironomus, Chironomus, Parachironomus, Dicrotendipes, and Cricotopus were explained by the increase in conductivity, dissolved oxygen, and temperature, and the decrease of the variables NO3, BOD, and Cu. In addition to this, the sites with urban-agricultural impact were clearly separated from sites with urban-industrial impact. The last one was more related to the increase in BOD, Cu, and NO3 that indicates moderate to poor water quality. In conclusion, we can infer that the physical and chemical variables are correlated with changes in the structure and distribution of the chironomid community and there are genera that respond differently at high and intermediate situations of disturbances. This knowledge contributes to the execution of strategies for the conservation and restoration of the lotic ecosystems.
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2Tgy1fY
Inequality promotes deforestation in Latin America
from Climate Change Skeptic Blogs via hj on Inoreader http://bit.ly/2FQddc7
Clinical Trials News
Would you like to help improve the clinical research experience for patients? We are interested in your opinion about reporting your symptoms for clinical trials. Please click the link below to complete this short, 5-minute survey. Your anonymous responses will be used for research purposes to better understand how to improve patient care. Complete the survey and provide your email address to be entered to win a $100 Visa gift card! Thank you for taking the time to provide your opinion.
Mon Jan 07, 2019 00:00
Do you or a loved one suffer from Schizophrenia? If so, Princeton Medical Institute located in Princeton, NJ is conducting a clinical research trial of an investigational treatment for Schizophrenia. We're seeking volunteers 18 to 65 years old who have been diagnosed with Schizophrenia Study-related exams, procedures, and medication are provided at no cost. Visit our website to learn more and submit your interest! Common Symptoms of Schizophrenia May Include: Withdrawal from reality Hallucinations...
Sun Jan 06, 2019 00:00
Click image to enlargeLocal dermatologists are conducting a clinical research study to test the effectiveness and safety of an investigational topical medication for Plaque Psoriasis.Qualified Participants Must:Be 12-16 years old Provide consent and be accompanied by a legal guardian at the time of consent signing Have an Investigator's Global Assessment (IGA) score of at least 3 Be willing to comply with all study instructions and commit to follow-up visits Females must not be pregnant and agree...
Fri Jan 04, 2019 00:00
Aggression refers to a behavior that can result in both physical and psychological harm to oneself, others or objects in the environment. Aggression is manifested verbally, mentally, and physically. Such behavior becomes maladaptive when it persists, occurs outside an acceptable social context, and is of an intensity, frequency, severity and/or duration detrimental to the child's interests. This is a double-blind, randomized, parallel group, two-arm, placebo-controlled study with flexible dosing...
Thu Jan 03, 2019 00:00
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...
Wed Jan 02, 2019 00:00
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...
Wed Jan 02, 2019 00:00
Does Your Child Struggle with Excessive Underarm Sweat?Consider Joining a Clinical Research Study of a New MedicationWake Research is enrolling participants in a study of an investigational medication for excessive underarm sweat in children and teens.
Wed Jan 02, 2019 00:00
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...
Wed Jan 02, 2019 00:00
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...
Wed Jan 02, 2019 00:00
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...
Wed Jan 02, 2019 00:00
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...
Wed Jan 02, 2019 00:00
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...
Wed Jan 02, 2019 00:00
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...
Wed Jan 02, 2019 00:00
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...
Wed Jan 02, 2019 00:00
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...
Wed Jan 02, 2019 00:00
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...
Wed Jan 02, 2019 00:00
If you are caring for someone with Alzheimer's disease, please consider the ROAD clinical research study, which will determine the safety and effectiveness of the multifunctional small moleculeAD-35 in patients with mild to moderate Alzheimer's disease (AD).Key Eligibility Criteria• Between 50 and 85 years of age (inclusive)• Diagnosed with probable AD in accordance with the National Institute on Aging and Alzheimer's Association (NIA-AA) criteria• Mini-Mental State Examination (MMSE) score of ≥>...
Wed Jan 02, 2019 00:00
Is your child is experiencing the following symptoms: trouble staying focused, interrupts others, hyper or impulsive or does not listen, OR has already been diagnosed with Attention Deficit Hyperactivity Disorder (ADHD)? If yes, learn more about a medical research study evaluating an investigational study drug in children 6 to 17 years of age.
Wed Jan 02, 2019 00:00
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that two presentations highlighting the potential of Advaxis vectors to generate T cell responses to a large percentage of neoantigens and to promote antigen spreading and potentially slow progression of prostate cancer, were presented at the 2019 Keystone Symposia on Cancer Vaccines, held January 19-24
Fri Jan 25, 2019 15:05
LONDON--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Inhibitors?src=hash" target="_blank"gt;#Inhibitorslt;/agt;--The global PD-1 and PD-L1 Inhibitors market is expected to post a CAGR of over 19% during the period 2019-2023, according to Technavio.
Fri Jan 25, 2019 14:00
The acquired rights will cover all potential indications in the hospital setting for the administration of inhaled AirNOvent at up to 80 parts per million. One of the The post Circassia to buy US, China marketing rights to AIT's AirNOvent appeared first on Pharmaceutical Business review.
Fri Jan 25, 2019 08:54
NV-5138 is a first-in-class, orally-active small molecule that directly activates mTORC1, the gatekeeper of cellular metabolism and renewal, which is suppressed in the brain of people suffering from The post Navitor Pharmaceuticals commences phase 1 clinical evaluation of NV-5138 for treatment-resistant depression appeared first on Pharmaceutical Business review.
Fri Jan 25, 2019 08:54
X-165 is a highly potent and selective small molecule inhibitor of Autotaxin owned by X-Rx. An initial advanced lead series that led to the identification of X-165 was The post FDA accepts X-Rx's IND application for X-165 to treat IPF appeared first on Pharmaceutical Business review.
Fri Jan 25, 2019 08:54
The second indication of Rubraca has been approved as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer The post EC approves Clovis' Rubraca to treat women with relapsed ovarian cancer appeared first on Pharmaceutical Business review.
Fri Jan 25, 2019 06:56
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 8, 2019 to discuss its 2018 operating results. Management will also provide a brief update on the business. Conference Call InformationTo access the live call by phone, dial 323-794-2093; the conference ID is 6271602. The call may also be a
Thu Jan 24, 2019 23:30
ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that its' founder and CEO, William Hearl, Ph.D., will present an overview of the company and its UNITE technology platform at the 2019 BIO CEO & Investor Conference on February 12, 2019 at 2:00 pm EST in the Hudson/Empire Room at the Marriott Marquis in New York City. About UNITE ITI's investigational UNITE platform, or UNiversal Intracellular Targeted Expression, is thought to work by encoding the Lysosomal Assoc
Thu Jan 24, 2019 23:05
Vermont Collaborative Partners with Netsmart to Alter Trajectory of Care for State's Most Vulnerable
OVERLAND PARK, Kan.--(BUSINESS WIRE)--Four member agencies of Vermont Care Partners (VCP) have come together to reshape the delivery and coordination of care through a partnership with Netsmart to deploy a unified technology platform. As value-based care quickly becomes reality, Lamoille County Mental Health Services, Northwestern Counseling and Support Services, United Counseling Services of Bennington and Washington County Mental Health Services will leverage the full suite of solutions from
Thu Jan 24, 2019 22:00
The treatment of patients with Bing-Neel syndrome (BNS) is not standardized. We included patients with Waldenström macroglobulinemia (WM) and a radiologic and/or cytologic diagnosis of BNS treated with ibrutinib monotherapy. Response assessment was based on criteria for BNS from the 8th International Workshop for WM. Survival from BNS diagnosis (BNS survival), survival from ibrutinib initiation to last follow-up or death (ibrutinib survival), and time from ibrutinib initiation to ibrutinib discontinuation...
Thu Jan 24, 2019 19:00
PRINCETON, N.J.--(BUSINESS WIRE)--Oyster Point Pharma to present a corporate overview at the BIO CEO & Investor Conference.
Thu Jan 24, 2019 17:33
ST. LOUIS, Mo.--(BUSINESS WIRE)--Midwest Vision Research Foundation at Pepose Vision Institute joins the AcuFocus IC-8® Lens clinical study for cataracts.
Thu Jan 24, 2019 16:05
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tamr Inc. today announced it has joined Accenture's open partner ecosystem, designed to help independent software vendors (ISVs) and life science companies team more effectively to accelerate drug discovery efforts and improve patient outcomes. The ecosystem is an integral part of Accenture's cloud-based informatics research platform, which has been designed to help life sciences organizations improve productivity, efficiency, and innovation in drug discovery.
Thu Jan 24, 2019 16:00
BOSTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24GMDA&src=ctag" target="_blank"gt;$GMDAlt;/agt;--Gamida Cell announces data from NAM-NK and NiCord® programs to be presented at 2019 TCT Annual Meeting
Thu Jan 24, 2019 15:32
WALTHAM, Mass.--(BUSINESS WIRE)--X-Rx Announces FDA Acceptance of IND Application for X-165
Thu Jan 24, 2019 15:15
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that Pnina Fishman, Chief Executive Officer of Can-Fite Biopharma, has issued a Letter to Shareholders, the full text of which follows below. Dear Can-Fite Shareholders, It has been a very busy and productive year at Can Fite BioPharma, filled with c
Thu Jan 24, 2019 14:30
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna announced several changes to its board of directors, reflecting the company's ongoing growth.
Thu Jan 24, 2019 14:30
BURLINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24ARQL&src=ctag" target="_blank"gt;$ARQLlt;/agt; lt;a href="https://twitter.com/hashtag/arql?src=hash" target="_blank"gt;#arqllt;/agt;--ArQule, Inc.'s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX: BSLN), announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of derazantinib (BAL087) and Roche's PD-L1-blocking immune-checkpoint inhibitor, atezolizumab (Tecentriq®),...
Thu Jan 24, 2019 14:00
LEXINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24CNCE&src=ctag" target="_blank"gt;$CNCElt;/agt; lt;a href="https://twitter.com/hashtag/CNCE?src=hash" target="_blank"gt;#CNCElt;/agt;--Concert began a Phase 1 single-ascending dose trial to evaluate the safety, tolerability, and PK profile of CTP 692 in healthy volunteers.
Thu Jan 24, 2019 14:00
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Ohio Supreme Court has dismissed a Petition filed by Capital Royalty Partners II, L.P. and affiliated entities. On August 27, 2018, Capital Royalty Partners II, L.P. and several affiliated entities ("CRG") filed a Petition with the Ohio Supreme Court seeking a
Thu Jan 24, 2019 14:00
NEW YORK--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24BMY&src=ctag" target="_blank"gt;$BMYlt;/agt;--Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results
Thu Jan 24, 2019 13:59
BridgeBio Pharma will also use the funds to expand its efforts on the development of medicines for patients with unmet needs. Both existing investors KKR and Viking Global The post BridgeBio Pharma raises $299.2m in financing round appeared first on Pharmaceutical Business review.
Thu Jan 24, 2019 13:17
Data from the Phase 1 study are expected in the second half of 2019. "The initiation of this Phase 1 study with IW-6463 marks an important milestone for The post Ironwood Pharmaceuticals initiates phase 1 trial of IW-6463 appeared first on Pharmaceutical Business review.
Thu Jan 24, 2019 11:20
Under the terms of the agreement, BioNTech will acquire all assets, employees and proprietary know-how for mAb generation from MAB Discovery. MAB Discovery will retain ownership of and The post BioNTech to acquire MAB Discovery's antibody generation unit appeared first on Pharmaceutical Business review.
Thu Jan 24, 2019 13:17
ZURICH & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Regulatory News: ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma Ltd., a company of Vifor Pharma Group, today announced that in light of the upcoming availability of data from the pivotal Phase III ADVOCATE trial – the largest controlled trial in active anti-neutrophil cytoplasmic antibody associated vasculitis (ANCA-associated vasculitis) – they have decided to withdraw the application for Conditional Marketing Authorisation (CM
Thu Jan 24, 2019 08:00
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") in connection with the commencement of a proposed initial public offering of its common stock. Gossamer Bio is offering 14,375,000 sha
Thu Jan 24, 2019 00:24
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced receipt of notification from the U.S. Food and Drug Administration (FDA) that the Company's ongoing Phase 3, randomized, double-blinded, placebo-controlled, pivotal study of axalimogene filolisbac (AXAL) in high-risk, locally advanced cervical cancer (AIM2CERV) has been placed on partial clinical
Wed Jan 23, 2019 23:05
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced the initiation of a Phase 1 study evaluating IW-6463 in healthy volunteers. IW-6463 is an orally administered central nervous system (CNS)-penetrant soluble guanylate cyclase (sGC) stimulator that is being developed for the treatment of serious and orphan CNS disorders. Data from the Phase 1 study are expected in the second half of 2019. "The initiation of this Phase 1 study with IW-6463 marks an im
Wed Jan 23, 2019 23:01
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences announced a publication in Nature that revealed a newly discovered mechanism underlying antitumor immunity.
Wed Jan 23, 2019 20:07
IRVINE, Calif.--(BUSINESS WIRE)--Modulated Imaging has raised $7 million in Series B funding to fund the commercialization of its Clarifi technology and clinical studies.
Wed Jan 23, 2019 19:30
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--World-renowned interventional cardiologist Martin Rothman has been named chief medical officer at VDI.
Wed Jan 23, 2019 19:05
An oral porcupine inhibitor, RXC004 has been designed to target the Wnt signaling pathway. The early-stage trial of the small molecule drug was temporarily stopped in March 2018 The post Redx gets regulatory nod to restart RXC004 clinical trial appeared first on Pharmaceutical Business review.
Wed Jan 23, 2019 17:43
VIENNA, Va.--(BUSINESS WIRE)--U.S. patent office issues CEL-SCI two patents for its LEAPS vaccine platform technology.
Wed Jan 23, 2019 16:20
NEW YORK--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/MDSO?src=hash" target="_blank"gt;#MDSOlt;/agt;--Medidata (NASDAQ:MDSO) today announced that it has entered into a three-year strategic collaboration with the World Economic Forum. The company becomes a Partner Member Associate and will participate in the WEF System Initiative focused on Shaping the Future of Health and Healthcare. The initiative has a goal of transforming the continuum of care – from prevention to diagnosis, treatment,...
Wed Jan 23, 2019 15:30
PARSIPPANY, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Ferring?src=hash" target="_blank"gt;#Ferringlt;/agt;--Sophie Opdyke, Pharm.D., MBA, will be responsible for building the Ferring Pharmaceuticals (U.S.) oncology division
Wed Jan 23, 2019 15:25
HOUSTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/backpain?src=hash" target="_blank"gt;#backpainlt;/agt;--InGeneron expands development pipeline with two studies for chronic backpain and wrist osteoarthritis, setting focus on orthopedic indications.
Wed Jan 23, 2019 15:00
PALO ALTO, Calif.--(BUSINESS WIRE)--BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases, today announced a new financing round of $299.2 million. The round was co-led by existing investors KKR and Viking Global Investors. Other existing investors participating included Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, and Hercules Capital; and they were joined by new investors Sequoia Capital, and a blue-chip long-term investor. The financing wil
Wed Jan 23, 2019 15:00
PHILADELPHIA--(BUSINESS WIRE)--Talee Bio, Inc., a development stage biopharmaceutical company focused on developing gene therapy treatments for cystic fibrosis, today announced agreements with the Cystic Fibrosis Foundation (CF Foundation) to fund the preclinical development of two mutation-agnostic gene therapy product candidates, TL-101 and TL-102. The CF Foundation committed up to $4.5 million to expedite the development of both product candidates for all people with cystic fibrosis, and par
Wed Jan 23, 2019 14:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the addition of Elizabeth (Liz) Barrett and George Golumbeski, Ph.D., to the company's board of directors. "We are extremely pleased to add these two experienced executives to Sage's board of directors. As Sage continues to advance its programs in development, adding an executive
Wed Jan 23, 2019 14:00
AUSTIN, Texas & HAMILTON, Ontario--(BUSINESS WIRE)--Triumvira appoints Andreas Bader as Senior Vice President of Research & Development and Joshua Carle as Vice President of Business Development.
Wed Jan 23, 2019 14:00
LOS ANGELES--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Breastfeeding?src=hash" target="_blank"gt;#Breastfeedinglt;/agt;--Supplementation with unique B3 vitamin nicotinamide riboside confers significant and enduring physiological benefits to mouse mothers and offspring.
Wed Jan 23, 2019 13:30
DUBLIN--(BUSINESS WIRE)--The "Idiopathic Pulmonary Fibrosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Idiopathic Pulmonary Fibrosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Idiopathic Pulmonary Fibrosis . The report includes information of marketed products including their product des
Wed Jan 23, 2019 13:24
The approval was based on data from the Phase 2 BLAST study in frontline and relapsed/refractory ALL, the largest prospective trial for MRD-positive ALL ever conducted. BLINCYTO, a The post EC approves Blincyto in patients with Philadelphia chromosome negative minimal residual disease-positive B-cell precursor ALL appeared first on Pharmaceutical Business review.
Wed Jan 23, 2019 11:52
RP-A501 is the Company's first adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease that is in development under a collaboration with the University of The post Rocket Pharmaceuticals announces clearance of IND for RP-A501 gene therapy for Danon disease appeared first on Pharmaceutical Business review.
Wed Jan 23, 2019 11:52
Tesaro acquisition will enable GSK to strengthen its pharmaceutical business; and expand its pipeline and commercial capability in oncology. Tesaro president and COO Dr Mary Lynne Hedley said: The post GSK closes acquisition of Tesaro for $5.1bn appeared first on Pharmaceutical Business review.
Wed Jan 23, 2019 11:52
NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it intends to offer and sell $150 million of its ordinary shares in an underwritten public offering. The company also intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of ordinary shares sold in the offering at the pu
Tue Jan 22, 2019 23:01
BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp® (NYSE: LH), a leading global life sciences company, today announced that it has been named to FORTUNE magazine's 2019 List of World's Most Admired Companies, making the annual list for the second consecutive year. The annual survey, conducted by FORTUNE and Korn Ferry, a global organizational consulting firm, is given to top executives, directors, and financial analysts to identify the companies that enjoy the strongest reputations within their indust
Tue Jan 22, 2019 17:35
BOSTON & MINNEAPOLIS--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24GMDA&src=ctag" target="_blank"gt;$GMDAlt;/agt;--Gamida Cell and Be The Match BioTherapies® announced a collaboration to improve outcomes for patients undergoing bone marrow transplantation.
Tue Jan 22, 2019 15:30
GUANGZHOU, China--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/arthritis?src=hash" target="_blank"gt;#arthritislt;/agt;--Bio-Thera Solutions announces the initiation of a Phase III clinical trial for BAT1806, a proposed biosimilar of Actemra® (Tocilizumab).
Tue Jan 22, 2019 15:08
SEATTLE--(BUSINESS WIRE)--LabConnect is pleased to announce a new service: LabConnect's global sample processing network (GSPN).
Tue Jan 22, 2019 15:00
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 7, 2019 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Thursday, February 7, 20191:30 p.m. Pacific Time / 4
Tue Jan 22, 2019 15:00
SAN LEANDRO, Calif.--(BUSINESS WIRE)--Data from ongoing P2 trial of Rainier's FGFR3-targeted antibody vofatamab to be presented at 2019 ASCO Genitourinary Cancers Symposium Feb 14 in SF
Tue Jan 22, 2019 15:00
FLAGSTAFF, Arizona--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) ha introducido hoy perfiles reducidos para los diámetros más utilizados de la endoprótesis para aorta torácica adaptable GORE® TAG® con el sistema de CONTROL ACTIVO. El perfil reducido permite a los médicos realizar reparaciones endovasculares torácicas (TEVAR) en pacientes con vasos más pequeños donde el acceso es difícil y la anatomía aórtica es tortuosa, lo que amplía la disponibilidad de la endoprótesis para aorta
Tue Jan 22, 2019 14:47
FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) introduceerde vandaag gereduceerde profielen voor de meest gebruikte diameters van de GORE® TAG® Conformable Thoracic Stent Graft met ACTIVE CONTROL System. Het gereduceerde profiel stelt artsen in staat om TEVAR uit te voeren bij patiënten met kleinere vaten waar de toegang moeilijk is en de aorta anatomie kronkelig is, waardoor de beschikbaarheid van Gore's thoracale stenttransplantaat wordt uitgebreid naar een groter
Tue Jan 22, 2019 14:47
WILMINGTON, Del.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24INCY&src=ctag" target="_blank"gt;$INCYlt;/agt;--Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease
Tue Jan 22, 2019 14:30
BLOOMINGTON, Ind.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/cookmedical?src=hash" target="_blank"gt;#cookmedicallt;/agt;--Today at the Leipzig Interventional Course (LINC), Cook Medical participated in significant discussion about the use of paclitaxel to treat patients suffering from PAD. Through several presentations to meeting attendees, data supported the use of paclitaxel-coated devices to help the more than 200 million1 patients globally who are fighting the disease. "We believe...
Tue Jan 22, 2019 14:10
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced positive results for its exploratory Phase 2 head-to-head study evaluating the efficacy, safety and tolerability of voclosporin ophthalmic solution (VOS 0.2%) versus Restasis®(cyclosporine ophthalmic emulsion 0.05%) for the treatment of dry eye syndrome (DES). Both drugs were shown to be well-tolerate
Tue Jan 22, 2019 14:00
LEXINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24CNCE&src=ctag" target="_blank"gt;$CNCElt;/agt; lt;a href="https://twitter.com/hashtag/AlopeciaAreata?src=hash" target="_blank"gt;#AlopeciaAreatalt;/agt;--Concert completed enrollment in its Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata.
Tue Jan 22, 2019 14:00
BEIJING--(BUSINESS WIRE)--Beijing-based Immunochina Pharmaceuticals today announced the closing of its $140 million RMB Series C financing (approximately $20.4 million in US Dollars). This financing will enable the company to expand its GMP-grade manufacturing capabilities while continuing clinical trials for its lead IM19 product targeting B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Non Hodgkin's Lymphoma, as well as advancing the development of its pipeline targeting multiple solid and li
Tue Jan 22, 2019 14:00
DUBLIN--(BUSINESS WIRE)--The "Aplastic Anemia - Pipeline Insight, 2019" drug pipelines report has been added to ResearchAndMarkets.com's offering. This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Aplastic Anemia development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, assoc
Tue Jan 22, 2019 13:40
DUBLIN--(BUSINESS WIRE)--The "Cluster Headache Syndrome - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Cluster Headache Syndrome development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental
Tue Jan 22, 2019 13:34
GLASGOW, Scotland--(BUSINESS WIRE)--TC BioPharm (TCB), a developer of CAR-T immuno-oncology products, including Gamma Delta T (GDT) cell therapies, today announced it has completed formulation of its first allogeneic GDT cell banks. The T cell banks provide TCB with core technology to develop a deep portfolio of next-generation CAR-T products directed against a wide variety of different cancer types, both hematological and solid tumors. The project was supported by funding from the European Uni
Tue Jan 22, 2019 12:55
Publication date: Available online 21 January 2019Source: Contemporary Clinical TrialsAuthor(s): Heather M. Johnson, Lisa Sullivan-Vedder, KyungMann Kim, Patrick E. McBride, Maureen A. Smith, Jamie N. LaMantia, Jennifer T. Fink, Megan R. Knutson Sinaise, Laura M. Zeller, Diane R. LauverAbstractYoung adults (18–39 year-olds) with hypertension have a higher lifetime risk for cardiovascular disease. However, less than 50% of young adults achieve hypertension control in the United States. Hypertension...
Tue Jan 22, 2019 13:13
The label extension has been granted to treat the most common form of CF based on data from a phase 3 open-label safety study in 60 patients. According The post EC approves Vertex's CF treatment Orkambi for children aged two to five years appeared first on Pharmaceutical Business review.
Tue Jan 22, 2019 12:25
In addition, a second compound, NP-135 was identified as an additional lead. Both NP-135 and NP-160 are one of a number of already approved compounds that Nash has The post Nash's NASH NP-160 shows repeated positive results in second pre-clinical study appeared first on Pharmaceutical Business review.
Tue Jan 22, 2019 12:25
DUBLIN--(BUSINESS WIRE)--The "Global Clinical Trials - Current Trends and Recent Advancement" report has been added to ResearchAndMarkets.com's offering. "Global Clinical Trials Current Trends and Recent Advancement", provides an in-depth assessment of the current trends in the number of clinical trials globally, Top 10 therapy area, geography wise clinical trials, YOY clinical trials in top 10 therapy area. An overview of clinical guidelines reforms has also been provided to show how regulator
Tue Jan 22, 2019 11:17
CAMBRIDGE, England--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/IBD?src=hash" target="_blank"gt;#IBDlt;/agt;--PredictImmune confirm Canadian patent grant which covers PredictImmune's intellectual property relating to methods for predicting autoimmune disease
Tue Jan 22, 2019 11:00
PCI has extended onsite controlled substance storage at its US commercial packaging locations in Philadelphia, PA and Rockford, IL, and will undertake further expansions as demand increases for The post PCI announces further investment in infrastructure for packaging of controlled substances appeared first on Pharmaceutical Business review.
Tue Jan 22, 2019 12:25
CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Wren Therapeutics ("Wren"), a biopharmaceutical company focused on drug discovery and development for protein misfolding diseases, today announces it has completed a Series A financing round. The company, formally founded in 2016, raised a total of £18 million from an international syndicate led by The Baupost Group with participation from LifeForce Capital and a number of high net worth individual investors. Protein molecules form the machinery that
Tue Jan 22, 2019 09:30
LONDON--(BUSINESS WIRE)--EMMAC, the European independent medical cannabis company, is pleased to announce the acquisition of a majority interest in Medalchemy, a fully-licensed GMP certified laboratory in Alicante, Spain. Medalchemy, a technology-based manufacturing company located on the premises of the University of Alicante, has more than a decade of experience in the research, development and manufacture of active pharmaceutical ingredients (APIs) and has submitted license applications to i
Tue Jan 22, 2019 09:00
ZURICH--(BUSINESS WIRE)--Re-analysis of pivotal study reveals: Proactive, High DOSAGE OF venofer®...
Tue Jan 22, 2019 08:00
SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals and Karolinska Institutet announced today a five-year extension of their collaboration to explore the potential of the human microbiome in reproductive medicine and women's health and gastroenterology. The collaboration brings together specialist expertise from Karolinska Institutet in early stage research, Rebiotix Inc. (acquired by Ferring in 2018), a late-stage clinical microbiome company, and Ferring's therapeutic area and co
Tue Jan 22, 2019 08:00
January 17, 2019 – REDWOOD CITY, Calif. and MINNEAPOLIS, Minn. – Proteus Digital Health®, Inc., Fairview Health Services, and University of Minnesota Health announced today that for the first time cancer patients are using digital...
Thu Jan 17, 2019 22:01
London UK; Philadelphia US; Geneva Switzerland - January 16, 2019 -- GSK and Medicines for Malaria Venture (MMV) today announced the publication of positive results from two phase III studies of single-dose tafenoquine for the radical cure...
Wed Jan 16, 2019 23:01
HIGH POINT, N.C.--(BUSINESS WIRE)--Jan. 16, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the publication of a paper in Science Translational Medicine showcasing the discovery and development of TTP399, an investigational, oral, small...
Wed Jan 16, 2019 22:01
THOUSAND OAKS, Calif., Jan. 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that as part of the Company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at...
Mon Jan 07, 2019 22:01
FLAGSTAFF, Arizona--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) meldete heute die Markteinführung reduzierter Profile für die am häufigsten verwendeten Durchmesser von GORE® TAG® Conformable Thoracic Stent Graft mit ACTIVE CONTROL System. Das reduzierte Profil ermöglicht es den Ärzten, bei Patienten mit kleineren Blutgefäßen eine thorakale endovaskuläre Aortenreparatur (TEVAR) durchzuführen, wenn der Zugang anspruchsvoll und die Aorta gewunden ist, um auf diese Weise die Einsatzmö
Mon Jan 21, 2019 22:37
FLAGSTAFF, Arizona--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) a présenté aujourd'hui des profils réduits des diamètres les plus couramment utilisés de l'endoprothèse thoracique conformable implantable GORE® TAG® dotée du système ACTIVE CONTROL. La réduction du profil permet aux médecins de procéder à une procédure TEVAR (réparation endovasculaire des anévrismes de l'aorte thoracique) chez les patients dont les vaisseaux sont étroits et difficiles d'accès et l'anatomie aortique t
Mon Jan 21, 2019 19:30
Riassunto: Gore lancia in Europa lo stent graft toracico conformabile GORE® TAG® con profili ridotti
FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) ha oggi lanciato profili ridotti per i diametri più comunemente utilizzati dello stent graft toracico conformabile GORE® TAG® con sistema ACTIVE CONTROL. Il profilo ridotto consente al personale medico di eseguire trattamenti endovascolari dell'aorta toracica (TEVAR) nei pazienti con vasi sanguigni più piccoli, di difficile accesso e con anatomia aortica tortuosa, ampliando la disponibilità dello stent graft toracico di
Mon Jan 21, 2019 16:18
TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Mon Jan 21, 2019 14:00
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. "Today's approval by the European Commission brings us one step closer to our goal of bringing treatment to all people living with CF," said Reshma K
Mon Jan 21, 2019 11:00
FLAGSTAFF, Ariz.--(BUSINESS WIRE)--Gore Introduces GORE® TAG® Conformable Thoracic Stent Graft with Reduced Profiles in Europe
Mon Jan 21, 2019 10:00
Promentis is developing SXC-2023 along with other compounds that engage System xc-, a central nervous system target addressing glutamatergic imbalance and oxidative stress, to treat trichotillomania and other The post Promentis Pharmaceuticals commences phase 2 studies for SXC-2023 targeting Glutamatergic mechanism appeared first on Pharmaceutical Business review.
Mon Jan 21, 2019 12:58
The collaboration will combine the immuno-oncology expertise and pipeline of Kyn Therapeutics with the capabilities of Celgene in development and commercialization of drugs in areas of high unmet The post Kyn Therapeutics, Celgene partner on immuno-oncology therapies development appeared first on Pharmaceutical Business review.
Mon Jan 21, 2019 09:02
In accordance with Zymeworks' 2014 licensing and collaboration agreement with Lilly, Zymeworks will receive a milestone payment of US$8.0 million for Lilly's submission of an IND application for The post Lilly's second immune-oncology candidate using Zymeworks' Azymetric platform to start clinical trials appeared first on Pharmaceutical Business review.
Mon Jan 21, 2019 12:58
TOKYO--(BUSINESS WIRE)--At a meeting held today, the Board of Directors of SanBio Co., Ltd. (hereinafter, the "Company") resolved to add a program for treatment of chronic motor deficit from cerebral hemorrhage as a new indication for SB623, a regenerative cell medicine developed by the Group. (Hereinafter, the "Group" refers to two companies, SanBio Co., Ltd., and SanBio, Inc.) 1. Details of the Decision As part of its mission to introduce new therapeutic drugs for the central nervous system,
Mon Jan 21, 2019 02:05
Publication date: Available online 19 January 2019Source: Contemporary Clinical TrialsAuthor(s): Richard I. Stein, Jaime R. Strickland, Rachel G. Tabak, Ann Marie Dale, Graham A. Colditz, Bradley A. EvanoffAbstractWeight-control is a major public health focus for preventing multiple obesity-related health conditions. While clinic-based intensive lifestyle interventions are successful, low-socioeconomic-status (SES) populations, which have a higher burden of obesity, are difficult to reach; thus,...
Sun Jan 20, 2019 13:44
Subscribe to:
Posts (Atom)
-
Media Alarms: Eating Meat Heats the Planet You may have noticed a media theme over recent months linking meat eating with climate change...
-
Association between Genetic Polymorphisms in microRNA Machinery Genes and Risk of Papillary Thyroid Carcinoma Thu Jun 27, 2019 03:00 ...
